NYSEAMERICAN:NAVB

Navidea Biopharmaceuticals - NAVB Stock Forecast, Price & News

$0.25

+0.01 (+4.21%)

(As of 11/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.24
▼
$0.26
50-Day Range: N/A
52-Week Range: $0.20
▼
$1.34

Volume: 95,522 shs
Average Volume: 171,820 shs
Market Capitalization: $7.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Stock

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Receive NAVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NAVB Stock News Headlines

November 28, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis

November 15, 2022 | seekingalpha.com

Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2022 Earnings Call Transcript

November 14, 2022 | finance.yahoo.com

CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results

November 14, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results

October 5, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

September 30, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders

September 27, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals, Inc. (NAVB)

September 15, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting

September 1, 2022 | markets.businessinsider.com

Navidea Biopharma To Assess Court's Judgment In Case Involving Attorney's Fees

September 1, 2022 | nasdaq.com

Navidea Opens New Sites In Phase 3 Trial In Rheumatoid Arthritis; Terminates MOU With Jubilant

September 1, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma

August 30, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update

August 18, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering

August 4, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering

August 1, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia

August 1, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering

July 25, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV

July 20, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

July 6, 2022 | morningstar.com

Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding | Morningstar

July 5, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding

May 24, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting

May 12, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results

April 20, 2022 | seekingalpha.com

Navidea reports initial data from phase 2b study of imaging agent in rheumatoid arthritis patients

April 20, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets

April 20, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NAVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NAVB Company Calendar

Last Earnings: 11/10/2021
Today: 11/30/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Diagnostic Substances
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NYSEAMERICAN:NAVB
Previous Symbol: NYSEMKT:NAVB
CUSIP: 63937X10
CIK: 810509
Web: www.navidea.com
Phone: (614) 793-7500
Fax: 614-793-7522
Employees: 11
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,720,000.00
Net Margins: -1,557.43%
Pretax Margin: -1,555.14%
Return on Equity: -116.36%
Return on Assets: -114.53%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.87
Quick Ratio: 1.83

Sales & Book Value

Annual Sales: $920,000.00
Price / Sales: 8.64
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.46 per share
Price / Book: 0.54

Miscellaneous

Outstanding Shares: 32,151,000
Free Float: 20,407,000
Market Cap: $7.95 million
Optionable: Optionable
Beta: 1.73

Key Executives

Ms. Erika L. Eves (Age 52)
VP of Fin. & Admin.
Comp: $213.25k

Dr. Michael Stanley Rosol Ph.D. (Age 54)
Sr. VP & Chief Medical Officer
Comp: $336.31k

Mr. Jeffrey G. Smith
VP of Operations

Key Competitors

View All Competitors

Insiders & Institutions

Group One Trading L.P.
Sold 95,600 shares on 11/9/2022
Ownership: 0.000%

View All Insider Transactions
View All Institutional Transactions

NAVB Stock - Frequently Asked Questions

Are investors shorting Navidea Biopharmaceuticals?: Navidea Biopharmaceuticals saw a decrease in short interest in October. As of October 31st, there was short interest totaling 114,400 shares, a decrease of 50.2% from the October 15th total of 229,900 shares. Based on an average daily volume of 157,400 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.5% of the shares of the company are sold short.
View Navidea Biopharmaceuticals' Short Interest.
How were Navidea Biopharmaceuticals' earnings last quarter?: Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) announced its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. The biopharmaceutical company earned $0.10 million during the quarter, compared to analyst estimates of $0.60 million. Navidea Biopharmaceuticals had a negative net margin of 1,557.43% and a negative trailing twelve-month return on equity of 116.36%.
What other stocks do shareholders of Navidea Biopharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include OPKO Health (OPK), Ampio Pharmaceuticals (AMPE), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Palatin Technologies (PTN), Trevena (TRVN), Agenus (AGEN), Dynavax Technologies (DVAX) and Genocea Biosciences (GNCA).
What is Navidea Biopharmaceuticals' stock symbol?: Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

Who are Navidea Biopharmaceuticals' major shareholders?: Navidea Biopharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Group One Trading L.P. (0.00%). Insiders that own company stock include Jed Latkin, John K Jr Scott and Malcolm G Witter.
View institutional ownership trends.
How do I buy shares of Navidea Biopharmaceuticals?: Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Navidea Biopharmaceuticals' stock price today?: One share of NAVB stock can currently be purchased for approximately $0.25.
How much money does Navidea Biopharmaceuticals make?: Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) has a market capitalization of $7.93 million and generates $920,000.00 in revenue each year. The biopharmaceutical company earns $-10,720,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.
How can I contact Navidea Biopharmaceuticals?: Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The official website for the company is www.navidea.com. The biopharmaceutical company can be reached via phone at (614) 793-7500, via email at ir@navidea.com, or via fax at 614-793-7522.

This page (NYSEAMERICAN:NAVB) was last updated on 11/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial